Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 347 188 M
EBIT 2017 -
Net income 2017 20 586 M
Finance 2017 53 844 M
Yield 2017 1,32%
Sales 2018 358 338 M
EBIT 2018 -
Net income 2018 25 614 M
Finance 2018 77 480 M
Yield 2018 1,40%
P/E ratio 2017 48,29
P/E ratio 2018 39,57
EV / Sales2017 3,00x
EV / Sales2018 2,84x
Capitalization 1 095 895 M
More Financials
Company
Kyowa Hakko Kirin Co., Ltd. is a holding company which engages in the manufacture and sale of medical and pharmaceutical products.It operates through the Pharmaceuticals and Bio-Chemicals segments.The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of Kyowa Hakko Kirin Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on KYOWA HAKKO KIRIN CO LTD
05:47p KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/27 KYOWA HAKKO KIRIN : Researchers Submit Patent Application, "RNAi PHARMACEUTICAL ..
04/27 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/20 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin plan a date with the FDA after..
04/18 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International ..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/07 Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatri..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/06 KYOWA HAKKO KIRIN : "Nucleic Acid That Inhibits Expression of Irf5" in Patent Ap..
04/06 KYOWA HAKKO KIRIN : Investigators from Kyowa Hakko Kirin Co Target Drug Developm..
More news
Sector news : Specialty & Advanced Pharmaceuticals
05:59pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
02:37pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
04/19Ultragenyx, Kyowa Hakko Kirin And Announce Positive 24-Week Data From Adult P.. 
04/07BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its pr.. 
01/31Kyowa Hakko Kirin : Notice of Recording of Extraordinary Losses in Non-consol.. 
2016Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug  
2016Kyowa Hakko Kirin : Application seeking Approval for Additional formulation o.. 
More tweets
Qtime:4
News from SeekingAlpha
04/10 3 THINGS IN BIOTECH YOU SHOULD LEARN : Volume 4
01/05 Ultragenyx and Kyowa Kirin announce MAA for KRN23 filed and accepted for revi..
2016 ArQule Is Undervalued Going Into Catalyst Events
Advertisement
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Full-screen chart
Technical analysis trends KYOWA HAKKO KIRIN...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 2 153  JPY
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Koichiro Nishikawa Independent Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO L..17.49%9 858
ABBVIE INC5.51%105 288
MERCK KGAA8.62%15 119
JAZZ PHARMACEUTICALS P..48.59%9 723
CONVATEC GROUP PLC31.55%7 714
ZHANGZHOU PIENTZEHUANG..24.18%5 006
More Results